Strategies for Optimizing Bispecific Antibody Design and Development

Not every antibody can be combined to produce well-behaved multispecifics. The valency and geometry of each design can determine the production, target engagement, and ultimately the requisite biological functions. In this case study, we selected two established antibody therapeutics, trastuzumab and a humanized OKT3, to produce 17 different bispecific formats to compare the feasibility of each format.